These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 15517621

  • 1. Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients.
    Wolfe F, Michaud K.
    J Rheumatol; 2004 Nov; 31(11):2115-20. PubMed ID: 15517621
    [Abstract] [Full Text] [Related]

  • 2. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 3. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS, Nordvåg BY, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
    [Abstract] [Full Text] [Related]

  • 4. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ.
    J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
    [Abstract] [Full Text] [Related]

  • 5. Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy.
    Wolfe F, Michaud K.
    J Rheumatol; 2007 Aug; 34(8):1674-83. PubMed ID: 17611989
    [Abstract] [Full Text] [Related]

  • 6. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [Abstract] [Full Text] [Related]

  • 7. Measuring the epidemiology of distress: the rheumatology distress index.
    Wolfe F, Skevington SM.
    J Rheumatol; 2000 Aug; 27(8):2000-9. PubMed ID: 10955344
    [Abstract] [Full Text] [Related]

  • 8. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
    Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A.
    J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
    [Abstract] [Full Text] [Related]

  • 9. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 10. Jaw pain: its prevalence and meaning in patients with rheumatoid arthritis, osteoarthritis, and fibromyalgia.
    Wolfe F, Katz RS, Michaud K.
    J Rheumatol; 2005 Dec; 32(12):2421-8. PubMed ID: 16331775
    [Abstract] [Full Text] [Related]

  • 11. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C, Pope JE, Truong D, Bombardier C, Widdifield J, Thorne JC, Paul Haraoui B, Psaradellis E, Sampalis J, Bonner A.
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [Abstract] [Full Text] [Related]

  • 12. Health status and perception of pain: a comparative study between female patients with hand osteoarthritis and rheumatoid arthritis.
    Slatkowsky-Christensen B, Mowinckel P, Kvien TK.
    Scand J Rheumatol; 2009 Aug; 38(5):342-8. PubMed ID: 19585382
    [Abstract] [Full Text] [Related]

  • 13. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
    Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C, Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.
    Arthritis Rheum; 2007 May 15; 57(4):679-85. PubMed ID: 17471545
    [Abstract] [Full Text] [Related]

  • 14. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
    Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL, Radstake TR, Netea MG, Roest M, Stalenhoef AF.
    Ann Rheum Dis; 2009 Jun 15; 68(6):868-72. PubMed ID: 18635596
    [Abstract] [Full Text] [Related]

  • 15. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S, Hafström I, Werner S, Carlström K, Tengstrand B.
    J Rheumatol; 2007 Jul 15; 34(7):1451-8. PubMed ID: 17477470
    [Abstract] [Full Text] [Related]

  • 16. Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales.
    Wolfe F, Michaud K, Li T.
    J Rheumatol; 2006 Oct 15; 33(10):1942-51. PubMed ID: 16960928
    [Abstract] [Full Text] [Related]

  • 17. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
    Popa C, Netea MG, de Graaf J, van den Hoogen FH, Radstake TR, Toenhake-Dijkstra H, van Riel PL, van der Meer JW, Stalenhoef AF, Barrera P.
    J Rheumatol; 2009 Apr 15; 36(4):724-30. PubMed ID: 19273452
    [Abstract] [Full Text] [Related]

  • 18. The effect of anti-TNF-α vs. DMARDs on fatigue in rheumatoid arthritis patients.
    van Hoogmoed D, Fransen J, Repping-Wuts H, Spee L, Bleijenberg G, van Riel PL.
    Scand J Rheumatol; 2013 Apr 15; 42(1):15-9. PubMed ID: 22992002
    [Abstract] [Full Text] [Related]

  • 19. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion.
    Straub RH, Pongratz G, Schölmerich J, Kees F, Schaible TF, Antoni C, Kalden JR, Lorenz HM.
    Arthritis Rheum; 2003 Jun 15; 48(6):1504-12. PubMed ID: 12794817
    [Abstract] [Full Text] [Related]

  • 20. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F, Michaud K.
    Arthritis Rheum; 2007 May 15; 56(5):1433-9. PubMed ID: 17469100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.